Home » FDA Approves Exalenz Liver Trial
FDA Approves Exalenz Liver Trial
Exalenz Bioscience has obtained US Food and Drug Administration (FDA) approval to begin the Phase III clinical trial for the company’s BreathID diagnostic device for liver damage.
Globes
Globes
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May